![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CNTN5 |
Gene summary for CNTN5 |
![]() |
Gene information | Species | Human | Gene symbol | CNTN5 | Gene ID | 53942 |
Gene name | contactin 5 | |
Gene Alias | HNB-2s | |
Cytomap | 11q22.1 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | O94779 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
53942 | CNTN5 | AEH-subject1 | Human | Endometrium | AEH | 3.29e-02 | 9.05e-02 | -0.3059 |
53942 | CNTN5 | AEH-subject3 | Human | Endometrium | AEH | 3.51e-03 | 1.12e-01 | -0.2576 |
53942 | CNTN5 | AEH-subject4 | Human | Endometrium | AEH | 1.83e-06 | 2.31e-01 | -0.2657 |
53942 | CNTN5 | AEH-subject5 | Human | Endometrium | AEH | 5.97e-26 | 6.89e-01 | -0.2953 |
53942 | CNTN5 | EEC-subject1 | Human | Endometrium | EEC | 3.51e-03 | 1.25e-01 | -0.2682 |
53942 | CNTN5 | EEC-subject4 | Human | Endometrium | EEC | 7.40e-03 | 1.45e-01 | -0.2571 |
53942 | CNTN5 | HTA12-15-2 | Human | Pancreas | PDAC | 3.78e-09 | 7.04e-01 | 0.2315 |
53942 | CNTN5 | HTA12-23-1 | Human | Pancreas | PDAC | 1.06e-18 | 1.38e+00 | 0.3405 |
53942 | CNTN5 | HTA12-25-1 | Human | Pancreas | PDAC | 9.43e-22 | 1.30e+00 | 0.313 |
53942 | CNTN5 | HTA12-26-1 | Human | Pancreas | PDAC | 2.52e-43 | 1.62e+00 | 0.3728 |
53942 | CNTN5 | HTA12-29-1 | Human | Pancreas | PDAC | 1.52e-52 | 1.19e+00 | 0.3722 |
53942 | CNTN5 | HTA12-30-1 | Human | Pancreas | PDAC | 2.27e-04 | 1.10e+00 | 0.3671 |
53942 | CNTN5 | HTA12-32-1 | Human | Pancreas | PDAC | 4.65e-02 | 7.40e-01 | 0.3624 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![]() | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00343299 | Endometrium | AEH | cell junction assembly | 78/2100 | 420/18723 | 4.80e-06 | 1.24e-04 | 78 |
GO:00508086 | Endometrium | AEH | synapse organization | 67/2100 | 426/18723 | 2.67e-03 | 1.94e-02 | 67 |
GO:003432914 | Endometrium | EEC | cell junction assembly | 79/2168 | 420/18723 | 8.37e-06 | 1.85e-04 | 79 |
GO:005080812 | Endometrium | EEC | synapse organization | 68/2168 | 426/18723 | 3.73e-03 | 2.49e-02 | 68 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CNTN5 | SNV | Missense_Mutation | rs201496247 | c.2057N>T | p.Thr686Met | p.T686M | O94779 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VQ-A91U-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
CNTN5 | deletion | Frame_Shift_Del | c.743delN | p.Gln249ArgfsTer23 | p.Q249Rfs*23 | O94779 | protein_coding | TCGA-IN-7806-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | epirubicin | CR | |||
CNTN5 | SNV | Missense_Mutation | rs190220140 | c.730N>T | p.Arg244Trp | p.R244W | O94779 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EL-A3ZM-01 | Thyroid | thyroid carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CNTN5 | SNV | Missense_Mutation | rs750623368 | c.3116N>C | p.Gly1039Ala | p.G1039A | O94779 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-EM-A3SX-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CNTN5 | insertion | Frame_Shift_Ins | novel | c.355_356insAA | p.Val119GlufsTer2 | p.V119Efs*2 | O94779 | protein_coding | TCGA-E8-A419-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CNTN5 | insertion | Frame_Shift_Ins | novel | c.357_358insGCTAGAAAACT | p.Leu121ArgfsTer5 | p.L121Rfs*5 | O94779 | protein_coding | TCGA-E8-A419-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CNTN5 | insertion | In_Frame_Ins | novel | c.830_831insAGACTTTGATTTTTTCAT | p.Asn277delinsLysAspPheAspPhePheIle | p.N277delinsKDFDFFI | O94779 | protein_coding | TCGA-EL-A3ZP-01 | Thyroid | thyroid carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
CNTN5 | insertion | Frame_Shift_Ins | novel | c.822_823insAAATTTG | p.Val275LysfsTer7 | p.V275Kfs*7 | O94779 | protein_coding | TCGA-ET-A40S-01 | Thyroid | thyroid carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |